Logo
Overview
For couples undergoing IVF, the number of viable embryos available for transfer is one of the most significant factors influencing the chance of a successful pregnancy. A groundbreaking study by Genea Fertility scientists has challenged long held assumptions about which embryos are suitable for use, leading to the birth of 70 healthy babies from embryos that would previously have been classified as unfit and discarded.

Among those 70 babies are 10 month old identical twin sisters Ella and Ruby Bent. Their parents Louise and Nick appeared on Nine's Today Extra to share their story and speak to the impact that Genea's industry leading genetic testing had on their IVF journey. For the Bent family, as for many others, access to this technology meant the difference between having embryos to transfer and having none.

At the heart of this research is Genea's commitment to advancing the science of embryo assessment. Traditional approaches to embryo selection have relied on visual grading, but genetic testing adds a deeper layer of analysis, identifying embryos with the potential to develop into healthy pregnancies that visual assessment alone might overlook. By expanding the criteria used to evaluate embryos, Genea's scientists have been able to give patients more options and, critically, more chances at achieving the family they have been hoping and working towards.

The implications extend beyond individual families. As IVF becomes an increasingly common pathway to parenthood in Australia, the ability to maximise the number of viable embryos from each cycle has profound significance for the thousands of patients who go through the process each year.

Genea's ongoing investment in research and scientific innovation is central to our mission of world leading fertility care. Every embryo assessed, every study conducted, and every family formed is part of that commitment.